Risk factors

Substantially all revenue depends on tax-advantaged health savings accounts and consumer-directed benefits. Growth relies heavily on depository partners, payment card interchange fees, and acquisitions. Extensive regulation spans healthcare, tax, banking, and data privacy laws.

Operating losses reached $1.7 billion as of December 31, 2024, with minimal revenues from licenses and grants.

Jackson Acquisition Co II completed its initial public offering on December 11, 2024, raising $230,000,000 in gross proceeds.

Kingstone Companies faces heavy geographic concentration risk with 96% of 2024 revenue derived from New York. Operations depend significantly on a small group of insurance brokers providing 51.2% of gross premiums. The business is heavily exposed to property catastrophes, weather events, and reinsurance availability.

Korro Bio faces substantial operating losses and an accumulated deficit of $266.6 million as of December 31, 2024.

LOB's risk profile is dominated by asset quality, dependence on SBA lending, and valuation risks in investments.

Lightwave Logic relies on ongoing research of electro-optic polymer materials, with funding projected to last only through April 2026. The company faces high capital needs, lengthy commercial qualification cycles, and intense competition from established photonics technologies.

Revenue heavily relies on high-volume sales of CleanCap, which have fluctuated significantly since 2022. The company faces ongoing customer demand unpredictability, product concentration risks, and intense industry competition. Substantial goodwill impairment charges highlight market and economic headwinds in nucleic acid production.

OmniAb faces substantial revenue concentration, with three partners generating 48% of 2024 revenue. The company operates at a continuing net loss, reporting $62.0 million in 2024. Success depends entirely on partners advancing platform-discovered therapeutics through clinical trials and regulatory approval.

Olema Pharmaceuticals is a clinical-stage biopharmaceutical company dependent on developing its product candidates palazestrant and OP-3136. The company has incurred net losses since inception, holds no approved products, and requires substantial additional capital. Operations face significant regulatory, clinical trial, competition, and financing risks.

Pangaea Logistics Solutions faces high cyclicality in the seaborne drybulk market, heavy reliance on Chinese import demand, and customer concentration risks.

Pyxis Oncology is a clinical-stage oncology company facing substantial accumulated deficits, operational losses, and ongoing capital needs. Its pipeline relies on novel therapeutic platforms, including micvotabart pelidotin, APXiMAB, and FACT, alongside extensive clinical and regulatory uncertainties.